Morepen Starts Commercial Supplies Under ₹825 Crore CDMO Mandate; Shares Rise

Mumbai, July 1: Morepen Laboratories Ltd. has begun commercial supplies under its ₹825 crore contract development and manufacturing organisation (CDMO) mandate, marking the transition of the programme from validation and qualification to full-scale commercial execution.

According to the company’s press release, the first commercial dispatch, valued at approximately ₹50 crore, has already been completed during the first quarter of FY2026-27.

The company expects to accelerate supplies over the coming quarters, with additional dispatches of around ₹225 crore planned during Q2 FY2026-27, subject to customer schedules and regulatory and commercial requirements.

Morepen said it is also expanding its manufacturing capabilities to support the programme. Production capacity is expected to reach nearly 600 KL by the end of the second quarter, with further expansion to 800 KL and 1,000 KL planned in subsequent phases.

Managing Director Sanjay Suri said the commencement of commercial supplies validates the company’s investment in manufacturing infrastructure and supply chain readiness. He added that Morepen remains focused on scaling operations, expanding capacity and strengthening its CDMO platform to serve additional customers and products.

Stock Market Snapshot

The announcement kept the Morepen Laboratories share price in focus during Wednesday’s session as investors reacted to the start of commercial execution under the large manufacturing mandate.

As of 9:28 AM IST on July 1, 2026, Morepen Laboratories shares were trading at ₹61.39, up 3.84%.

The commercial rollout is significant because it converts a previously announced order into revenue-generating execution. Investors will now watch the pace of quarterly dispatches and capacity expansion as indicators of how quickly the company can scale the programme.

Company Background

Morepen Laboratories is a pharmaceutical and healthcare company with operations spanning active pharmaceutical ingredients (APIs), finished formulations, diagnostics and consumer healthcare products. Alongside its branded healthcare business, the company has been expanding its CDMO operations to serve domestic and international pharmaceutical customers.

The company continues to invest in manufacturing infrastructure, regulatory capabilities and research to strengthen its position in the global pharmaceutical supply chain.

Conclusion

The commencement of commercial supplies represents an important milestone in Morepen Laboratories’ ₹825 crore CDMO programme. With the first ₹50 crore dispatch completed and larger shipments planned over the next quarter, the company has moved from preparation to execution. The market will closely track delivery schedules, capacity ramp-up and revenue contribution from the mandate in the coming quarters.

Source:

https://www.nseindia.com/get-quote/equity/MOREPENLAB/Morepen-Laboratories-Limited

https://nsearchives.nseindia.com/corporate/MOREPENLAB_01072026084358_Press_release.pdf